Exploiting hiPSC-derived cardiomyocytes to recapitulate heart failure phenotype in vitro

8 July 2026 (10:30 - 12:30)

Organised by:

42 More presentations in this session

Presentation thumbnail

A ZFPM2 regulatory region associated to Brugada syndrome plays an essential role in cardiac electrical activity and development

Presentation thumbnail

Mechanobiological distinction of focal and conductive arrhythmias by AFM

Presentation thumbnail

Promising QT-shortening effect of the endocannabinoid N-arachidonoyl-L-Serine (ARA-S) in a transgenic rabbit model of long QT syndrome type 1

Presentation thumbnail

Human living cardiac slices as a platform for antiarrhythmic drug testing

Presentation thumbnail

Electrophysiological characterization of human cardioids at different maturation stages

Access the full session

Session thumbnail

POSTER SESSION 2

The Event

Event poster

50th EWGCCE Meeting 2026

8 July 2026 10:30 CET

You may be interested in

Webinar

Induced-pluripotent stem cells (iPSC) technology for cardiac repair

17 March 2022

Congress Presentation

Integrated transcriptomic and regulatory RNA sequencing and machine-learning driven analyses identify molecular signatures underlying human heart failure

21 May 2023

Congress Presentation

Automated patch-clamp of human induced pluripotent stem cell (hiPSC) derived atrial cardiomyocytes as a promising technique to determine the electrophysiological impact of genetic risk variants

29 August 2025

Congress Presentation

Atrial cardiomyocytes lose contractile reserve with increased frequency and adrenergic stimulation in a murine HFpEF model

30 August 2026

ESC 365 is supported by

novartis

Explore sponsored resources

novo-nordisk

Explore sponsored resources

ESC 365 is supported by

novartis

Explore sponsored resources

novo-nordisk

Explore sponsored resources